Health Care [ 4/12 ] | Pharmaceuticals [ 22/74 ]
NASDAQ | Common Stock
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial.
It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy.
Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 25, 25 | -0.31 Increased by +22.50% | -0.29 Decreased by -7.53% |
| Nov 5, 24 | -0.46 Decreased by -18.79% | -0.41 Decreased by -13.00% |
| Jul 31, 24 | 0.87 Increased by +328.95% | -0.01 Increased by +8.80 K% |
| May 13, 24 | -0.43 Decreased by -4.88% | -0.44 Increased by +2.27% |
| Feb 27, 24 | -0.40 Increased by +20.00% | -0.43 Increased by +6.98% |
| Nov 7, 23 | -0.39 Increased by +23.53% | -0.43 Increased by +9.30% |
| Aug 3, 23 | -0.38 Increased by +54.22% | -0.44 Increased by +13.64% |
| May 15, 23 | -0.41 Increased by +35.94% | -0.46 Increased by +10.87% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -16.57 M Increased by +33.07% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -21.70 M Increased by +9.66% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 80.00 M Increased by +8.99 K% | 55.41 M Increased by +332.98% | Increased by +69.26% Increased by +102.56% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -26.87 M Decreased by -24.29% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 871.00 K Increased by +27.15% | -24.76 M Decreased by -4.77% | Decreased by -2.84 K% Increased by +17.61% |
| Sep 30, 23 | 759.00 K Decreased by -35.84% | -24.02 M Increased by +0.14% | Decreased by -3.16 K% Decreased by -55.64% |
| Jun 30, 23 | 880.00 K Decreased by -53.24% | -23.78 M Increased by +30.19% | Decreased by -2.70 K% Decreased by -49.29% |
| Mar 31, 23 | 295.00 K Decreased by -88.62% | -21.62 M Increased by +16.40% | Decreased by -7.33 K% Decreased by -634.57% |